Last reviewed · How we verify
NCT04290325
HMPL-453 in Advanced Malignant Mesothelioma
Phase 2 trial testing HMPL-453 in Advanced Malignant Mesothelioma in 27 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Hutchison Medipharma Limited |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 30 December 2019 |
| Primary completion | 30 November 2022 |
| Estimated completion | 17 March 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- HMPL-453 — full drug profile →
Conditions studied
- Advanced Malignant Mesothelioma — all drugs for Advanced Malignant Mesothelioma →
Sponsor
Hutchison Medipharma Limited — full company profile →
Who can join
18 and older, any sex, with Advanced Malignant Mesothelioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting FGFR for cancer therapy.
Zhang P, Yue L, Leng Q, Chang C, et al · · 2024 · cited 64× · PMID 38831455 · DOI 10.1186/s13045-024-01558-1
Verify or expand the search:
- PubMed search for NCT04290325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HMPL-453
Trials testing the same drug.
- NCT05930119 — HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study · Phase 1 · completed
- NCT04353375 — HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma · Phase 2, PHASE3 · recruiting
- NCT03160833 — A Study of HMPL-453 in Patients With Advanced Solid Malignancies · Phase 1, PHASE2 · unknown
Other Hutchison Medipharma Limited trials
Trials by the same sponsor.
- NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
- NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
- NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
- NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
- NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04290325 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
- Last refreshed: 16 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04290325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing